Adjunctive Local Application of Lidocaine During Scleral Buckling Under General Anesthesia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2010 by Isfahan University of Medical Sciences.
Recruitment status was  Recruiting
Information provided by:
Isfahan University of Medical Sciences Identifier:
First received: August 9, 2011
Last updated: August 15, 2011
Last verified: January 2010
The purpose of this study is to evaluate the effect of topical lidocaine in scleral buckling surgery.

Condition Intervention Phase
Retinal Detachment
Drug: lidocaine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Isfahan University of Medical Sciences:

Primary Outcome Measures:
  • intraoperative heart rate measurement [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]
  • decrease in pain and nausea,vomiting after surgery [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]
  • decrease in ocr after application of topical lidocaine [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]
  • postoperative nausea and vommitting [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]
  • postoperative pain [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: January 2010
Estimated Study Completion Date: September 2011
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: lidocaine Drug: lidocaine
to evaluate the effect of lidocaine on oculocardiac reflex during the surgery


Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Retinal detachment
  • Retinal tear less than 3 hour clock

Exclusion Criteria:

  • Vitreous hemorrhage
  • Proliferative vitreoretinopathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01417572

Contact: Amin Masjedi, MD +983112211915

Iran, Islamic Republic of
Isfahan University of Medical Sciences Recruiting
Isfahan, Iran, Islamic Republic of, 7864329800
Contact: amin masjedi, MD    +983112211915   
Principal Investigator: Amin Masjedi, MD         
Sponsors and Collaborators
Isfahan University of Medical Sciences
  More Information

Responsible Party: isfahan university of medical sciences Identifier: NCT01417572     History of Changes
Other Study ID Numbers: 199 
Study First Received: August 9, 2011
Last Updated: August 15, 2011
Health Authority: Iran: Ministry of Health

Additional relevant MeSH terms:
Retinal Detachment
Eye Diseases
Retinal Diseases
Anesthetics, Local
Anti-Arrhythmia Agents
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents
Sodium Channel Blockers
Voltage-Gated Sodium Channel Blockers processed this record on May 26, 2016